Fundamental Analysis of XILIO THERAPEUTICS INC(NASDAQ:XLO) stock

Fundamental Rating

Taking everything into account, XLO scores 2 out of 10 in our fundamental rating. XLO was compared to 587 industry peers in the Biotechnology industry. While XLO seems to be doing ok healthwise, there are quite some concerns on its profitability. XLO is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year XLO has reported negative net income.

XLO had a negative operating cash flow in the past year.

In the past 5 years XLO always reported negative net income.

In the past 5 years XLO always reported negative operating cash flow.

1.2 Ratios

XLO's Return On Assets of -125.42% is on the low side compared to the rest of the industry. XLO is outperformed by 83.93% of its industry peers.

XLO has a Return On Equity of -207.50%. This is in the lower half of the industry: XLO underperforms 71.62% of its industry peers.

		Industry Rank	Sector Rank
ROA	-125.42%
ROE	-207.5%
ROIC	N/A

ROA(3y)-74.51%

ROA(5y)-80.65%

ROE(3y)-110.63%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for XLO so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, XLO has more shares outstanding

Compared to 1 year ago, XLO has an improved debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -10.13, we must say that XLO is in the distress zone and has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -10.13, XLO is doing worse than 76.75% of the companies in the same industry.

There is no outstanding debt for XLO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-10.13

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 3.02 indicates that XLO has no problem at all paying its short term obligations.

XLO has a worse Current ratio (3.02) than 66.50% of its industry peers.

XLO has a Quick Ratio of 3.02. This indicates that XLO is financially healthy and has no problem in meeting its short term obligations.

Looking at the Quick ratio, with a value of 3.02, XLO is doing worse than 65.13% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	3.02
Quick Ratio	3.02

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

XLO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.66%, which is quite good.

EPS 1Y (TTM)13.66%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q21.95%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2QN/A

3.2 Future

The Earnings Per Share is expected to grow by 12.39% on average over the next years. This is quite good.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y36.24%

EPS Next 2Y22.38%

EPS Next 3Y12.79%

EPS Next 5Y12.39%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

XLO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year XLO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as XLO's earnings are expected to grow with 12.79% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y22.38%

EPS Next 3Y12.79%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for XLO!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

XILIO THERAPEUTICS INC

NASDAQ:XLO (5/15/2024, 9:03:58 AM)

1.11

+0.02 (+1.83%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap40.97M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-125.42%
ROE	-207.5%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	3.02
Quick Ratio	3.02
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)13.66%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y36.24%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

XILIO THERAPEUTICS INC (XLO)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens